Raised serum APRIL levels in patients with systemic lupus erythematosus

T. Koyama, H. Tsukamoto, Y. Miyagi, D. Himeji, J. Otsuka, H. Miyagawa, M. Harada, T. Horiuchi

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Objective: To determine whether serum levels of a proliferation-inducing ligand (APRIL) are raised in patients with systemic lupus erythematosus (SLE) and correlate with autoantibody titres or disease activity, or both. Methods: Serum samples from 48 patients with SLE, 41 normal healthy subjects, and 21 patients with rheumatoid arthritis (RA) were assayed for APRIL by enzyme linked immunosorbent assay. Medical charts were retrospectively reviewed for autoantibody titres and immunoglobulin levels. Disease activity was assessed using the British Isles Lupus Assessment Group (BILAG) index. Results: The APRIL levels in the serum samples from patients with SLE were significantly higher than in those from healthy controls and those from patients with RA. Serum APRIL levels did not correlate with serum IgG and IgM levels, but had a tendency to correlate with anti-double stranded DNA antibody titres. Moreover, serum APRIL levels correlated significantly with musculoskeletal manifestations among patients with SLE when assessed by the BILAG index. Conclusion: APRIL may be an important factor in raised autoantibody titres and musculoskeletal disease in patients with SLE. Patients with raised serum APRIL levels may be ideal candidates for therapeutic targeting of APRIL.

Original languageEnglish
Pages (from-to)1065-1067
Number of pages3
JournalAnnals of the Rheumatic Diseases
Volume64
Issue number7
DOIs
Publication statusPublished - Jul 1 2005

Fingerprint

Systemic Lupus Erythematosus
Ligands
Serum
Autoantibodies
Rheumatoid Arthritis
Musculoskeletal Diseases
Immunosorbents
Immunoglobulin M
Immunoglobulins
Assays
Healthy Volunteers
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Antibodies
DNA
Enzymes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Raised serum APRIL levels in patients with systemic lupus erythematosus. / Koyama, T.; Tsukamoto, H.; Miyagi, Y.; Himeji, D.; Otsuka, J.; Miyagawa, H.; Harada, M.; Horiuchi, T.

In: Annals of the Rheumatic Diseases, Vol. 64, No. 7, 01.07.2005, p. 1065-1067.

Research output: Contribution to journalArticle

Koyama, T, Tsukamoto, H, Miyagi, Y, Himeji, D, Otsuka, J, Miyagawa, H, Harada, M & Horiuchi, T 2005, 'Raised serum APRIL levels in patients with systemic lupus erythematosus', Annals of the Rheumatic Diseases, vol. 64, no. 7, pp. 1065-1067. https://doi.org/10.1136/ard.2004.022491
Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2005 Jul 1;64(7):1065-1067. https://doi.org/10.1136/ard.2004.022491
Koyama, T. ; Tsukamoto, H. ; Miyagi, Y. ; Himeji, D. ; Otsuka, J. ; Miyagawa, H. ; Harada, M. ; Horiuchi, T. / Raised serum APRIL levels in patients with systemic lupus erythematosus. In: Annals of the Rheumatic Diseases. 2005 ; Vol. 64, No. 7. pp. 1065-1067.
@article{2b2605306e9e439cbdc8a293ec4b51c1,
title = "Raised serum APRIL levels in patients with systemic lupus erythematosus",
abstract = "Objective: To determine whether serum levels of a proliferation-inducing ligand (APRIL) are raised in patients with systemic lupus erythematosus (SLE) and correlate with autoantibody titres or disease activity, or both. Methods: Serum samples from 48 patients with SLE, 41 normal healthy subjects, and 21 patients with rheumatoid arthritis (RA) were assayed for APRIL by enzyme linked immunosorbent assay. Medical charts were retrospectively reviewed for autoantibody titres and immunoglobulin levels. Disease activity was assessed using the British Isles Lupus Assessment Group (BILAG) index. Results: The APRIL levels in the serum samples from patients with SLE were significantly higher than in those from healthy controls and those from patients with RA. Serum APRIL levels did not correlate with serum IgG and IgM levels, but had a tendency to correlate with anti-double stranded DNA antibody titres. Moreover, serum APRIL levels correlated significantly with musculoskeletal manifestations among patients with SLE when assessed by the BILAG index. Conclusion: APRIL may be an important factor in raised autoantibody titres and musculoskeletal disease in patients with SLE. Patients with raised serum APRIL levels may be ideal candidates for therapeutic targeting of APRIL.",
author = "T. Koyama and H. Tsukamoto and Y. Miyagi and D. Himeji and J. Otsuka and H. Miyagawa and M. Harada and T. Horiuchi",
year = "2005",
month = "7",
day = "1",
doi = "10.1136/ard.2004.022491",
language = "English",
volume = "64",
pages = "1065--1067",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "7",

}

TY - JOUR

T1 - Raised serum APRIL levels in patients with systemic lupus erythematosus

AU - Koyama, T.

AU - Tsukamoto, H.

AU - Miyagi, Y.

AU - Himeji, D.

AU - Otsuka, J.

AU - Miyagawa, H.

AU - Harada, M.

AU - Horiuchi, T.

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Objective: To determine whether serum levels of a proliferation-inducing ligand (APRIL) are raised in patients with systemic lupus erythematosus (SLE) and correlate with autoantibody titres or disease activity, or both. Methods: Serum samples from 48 patients with SLE, 41 normal healthy subjects, and 21 patients with rheumatoid arthritis (RA) were assayed for APRIL by enzyme linked immunosorbent assay. Medical charts were retrospectively reviewed for autoantibody titres and immunoglobulin levels. Disease activity was assessed using the British Isles Lupus Assessment Group (BILAG) index. Results: The APRIL levels in the serum samples from patients with SLE were significantly higher than in those from healthy controls and those from patients with RA. Serum APRIL levels did not correlate with serum IgG and IgM levels, but had a tendency to correlate with anti-double stranded DNA antibody titres. Moreover, serum APRIL levels correlated significantly with musculoskeletal manifestations among patients with SLE when assessed by the BILAG index. Conclusion: APRIL may be an important factor in raised autoantibody titres and musculoskeletal disease in patients with SLE. Patients with raised serum APRIL levels may be ideal candidates for therapeutic targeting of APRIL.

AB - Objective: To determine whether serum levels of a proliferation-inducing ligand (APRIL) are raised in patients with systemic lupus erythematosus (SLE) and correlate with autoantibody titres or disease activity, or both. Methods: Serum samples from 48 patients with SLE, 41 normal healthy subjects, and 21 patients with rheumatoid arthritis (RA) were assayed for APRIL by enzyme linked immunosorbent assay. Medical charts were retrospectively reviewed for autoantibody titres and immunoglobulin levels. Disease activity was assessed using the British Isles Lupus Assessment Group (BILAG) index. Results: The APRIL levels in the serum samples from patients with SLE were significantly higher than in those from healthy controls and those from patients with RA. Serum APRIL levels did not correlate with serum IgG and IgM levels, but had a tendency to correlate with anti-double stranded DNA antibody titres. Moreover, serum APRIL levels correlated significantly with musculoskeletal manifestations among patients with SLE when assessed by the BILAG index. Conclusion: APRIL may be an important factor in raised autoantibody titres and musculoskeletal disease in patients with SLE. Patients with raised serum APRIL levels may be ideal candidates for therapeutic targeting of APRIL.

UR - http://www.scopus.com/inward/record.url?scp=21344441005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344441005&partnerID=8YFLogxK

U2 - 10.1136/ard.2004.022491

DO - 10.1136/ard.2004.022491

M3 - Article

C2 - 15576416

AN - SCOPUS:21344441005

VL - 64

SP - 1065

EP - 1067

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 7

ER -